Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Jan 31;111(2):znad379.
doi: 10.1093/bjs/znad379.

Defining benchmarks for total and distal gastrectomy: global multicentre analysis

Marcel André Schneider  1 , Jeesun Kim  2 , Felix Berlth  3 , Yutaka Sugita  4 , Peter P Grimminger  3 , Takeshi Sano  4 , Riccardo Rosati  5 , Gian Luca Baiocchi  6 , Maria Bencivenga  7 , Giovanni De Manzoni  7 , Souya Nunobe  4 , Han-Kwang Yang  2 , Christian Alexander Gutschow  1 ; GastroBenchmark Consortium; GASTRODATA Consortium
Collaborators, Affiliations
Multicenter Study

Defining benchmarks for total and distal gastrectomy: global multicentre analysis

Marcel André Schneider et al. Br J Surg. .
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Factors prediciting occurence of complications after gastrectomy a OR plot of multivariable logistic regression model assessing predictive factors for occurrence of overall complications after gastrectomy in benchmark patients (1569 patients). b OR plot of multivariable logistic regression model assessing predictive factors for occurrence of overall complications after gastrectomy in non-benchmark patients (7787 patients).
See this image and copyright information in PMC

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424 - PubMed
    1. Arnold M, Ferlay J, van Berge Henegouwen MI, Soerjomataram I. Global burden of oesophageal and gastric cancer by histology and subsite in 2018. Gut 2020;69:1564–1571 - PubMed
    1. Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KBet al. . Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol 2016;17:1697–1708 - PubMed
    1. Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper Set al. . Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 2019;393:1948–1957 - PubMed
    1. Guller U, Warschkow R, Ackermann CJ, Schmied B, Cerny T, Ess S. Lower hospital volume is associated with higher mortality after oesophageal, gastric, pancreatic and rectal cancer resection. Swiss Med Wkly 2017;147:w14473. - PubMed

Publication types